28/06/2007 13:00:00

Quantum Genomics Corp Partners with Inserm and CNRS in Hypertension Drug Development

Quantum Genomics Corp. (QGC), a global biotech company developing

new drugs for metabolic and cardiovascular diseases, announced

partnership agreements with Inserm, the French national institute for

health and medical research and the CNRS, France´s national center for

scientific research, and University Paris Descartes. The agreement

brings together some of the best scientific skills in the field of

cardiovascular diseases from two leading life science research

organizations and a premier university along with biotechnology

business experience from QGC, to successfully co-develop innovative

drugs.

The agreement covers a lead molecule derived from discoveries by

teams led respectively by Dr Catherine Llorens-Cortes, director of

Inserm Unit 691, based in the College de France and by Prof. Bernard

P. Roques at Inserm Unit 640, itself based in the University of Paris

Descartes.

The purpose of the agreement is to co-develop innovative drugs for

hypertension and related cardiovascular diseases. Under the terms of

the contract, QGC acquires rights to exploit three patents and

associated know-how. Inserm and CNRS will work on the physiopathology,

chemistry and the understanding of the compound´s mechanism of action

whereas QGC will handle preclinical and clinical development and

regulatory aspects.

The first lead molecule to be developed will be QGC001, a new

chemical entity. This compound acts according to a new biological

mechanism with a huge potential to facilitate control of blood

pressure in patients who are resistant to currently available

anti-hypertension drugs. QGC expects to start the first clinical trial

in humans in 2008.

"We are delighted to be partnering with Inserm and CNRS, two of

the world´s leading healthcare research organizations," said Lionel

Segard, Chairman and CEO of QGC. "This project lets QGC demonstrate

its ability to develop new drugs in compliance with international

regulatory guidelines. It also significantly reinforces QGC´s

potential in R&D in the field of cardiovascular diseases."

"This partnership with QGC gives us an excellent opportunity to

accelerate the pre-clinical and clinical development of a project

based on work carried out in our labs in close cooperation with

Bernard Roques´ team," said Catherine Llorens Cortes, director of

Inserm Unit 691.

Cardiovascular diseases are one of the main causes of death in

humans. Hypertension in particular is one of the major determining

factors in premature death. The risk of myocardial infarction, stroke,

kidney failure, heart failure or other complications doubles with

every 20/10mmHg rise in blood pressure. At least 30% of people have

hypertension. Hundreds of millions of people worldwide suffer from

hypertension complications despite medical advice on food and health

habits and the existence of several treatments. The market for

hypertensive drugs is expected to double between 2005 and 2010.

About Quantum Genomics Corp.

QGC is a biotechnology company seeking to develop new therapies in

areas where an unmet medical need exists. QGC focus is on

metabolism-related diseases and cardiovascular pathologies. It will

co-develop some products with academic teams and will set up strategic

alliances and commercial partnerships to cover all areas of research

in life sciences.

The company is headquartered in Jersey City, New Jersey, USA. It

has a European office in France under the leadership of Lionel Segard.

For more information go to www.Quantum-Genomics.com

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
29 Aug
 
Har man en halv times tid denne weekend kan den med fordel bruges på to ting: Dels på investeringsdi..
28
01 Sep
7-ST.L-24-GB
Søde venner. Mon Ami's!   I svære tider skal sjælen sankes, sårene slikkes og ego'et poleres af. Det..
21
30 Aug
OMXC20
20
28 Aug
OMXC20CAP
Så sluttede fredagen og igen tog jeg fejl.I tirsdags var jeg helt sikker på at frygten ville tage ti..
20
03 Sep
CHR
Goodwrench, få dig dog et liv istedet for at blande dig i alle tråde her på siden. Du har jo ikke no..
18
29 Aug
NOVO-B
Victoza er det mest solgte, det mest sikre og det mest gennemprøvede type 2 diabetes på markedet.   ..
12
28 Aug
 
De viser det på Ramasjang
12
31 Aug
FING-B
Kære Wiseguy, Solo, ready, Netzoom og alle jer andre ægte interesserede  fing-ejere. Kunne I ikke ov..
11
28 Aug
EI
Det vidste jeg godt med al den interesse, der er for mine guldkorn.   Reklamekronerne fosser ind i E..
10
31 Aug
 
HVIS du vil have aktien til åbningskursen - så kan du bare lægge en ordre på f eks 2 kr istedet for ..
9

Form 8.3 - Royal Dutch Shell Plc

02/09/2015 15:25:33
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE ..

Form 8.3 - Royal Dutch Shell PLC

02/09/2015 13:50:52
FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% O..

Form 8.5 (EPT/RI) - Innovation Group plc

02/09/2015 09:15:18
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
ALSTOM SA : Alstom to build HVDC VSC converter stations for the France-Italy transmission link
2
Medtronic Reports First Quarter Financial Results
3
Pentair and Urban Organics Collaborate to Advance Aquaponics Industry
4
Solidium Oy's half year report from 1 January to 30 June 2015 and annual financial statements: CLEAR IMPROVEMENT IN THE YIELD OF EQUITY INVESTMENTS AFTER A WEAK FIRST HALF OF THE FINANCIAL YEAR
5
FPC's touch fingerprint sensor FPC1025 in Huawei Mate S and G8 smartphones

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2015   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
04 September 2015 02:26:50
(UTC) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20150903.1 - EUROWEB2 - 2015-09-04 03:26:50 - 2015-09-04 02:26:50 - 1000 - Website: OKAY